TRK融合-话题@MedSci

#TRK融合#

7篇内容 | 525人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2049797, encodeId=40fe2049e9775, content=<a href='/topic/show?id=321a1e8361c' target=_blank style='color:#2F92EE;'>#TRK融合#</a>, objectTitle=JCO Precision Oncol：NTRK融合在儿童肿瘤中比预期的更常见, objectType=article, longId=205799, objectId=475b205e990c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=475b205e990c, replyNumber=0, likeNumber=50, createdTime=2021-05-03, rootId=0, userName=Tommy1949, userId=e5bc315, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=475b205e990c, moduleTitle=JCO Precision Oncol：NTRK融合在儿童肿瘤中比预期的更常见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=475b205e990c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2049794, encodeId=c9fb2049e9499, content=<a href='/topic/show?id=321a1e8361c' target=_blank style='color:#2F92EE;'>#TRK融合#</a>, objectTitle=Lancet Oncol：Larotrectinib治疗TRK融合阳性晚期实体瘤, objectType=article, longId=189095, objectId=34b1189095d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=34b1189095d4, replyNumber=0, likeNumber=41, createdTime=2020-08-15, rootId=0, userName=Tommy1949, userId=e5bc315, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=34b1189095d4, moduleTitle=Lancet Oncol：Larotrectinib治疗TRK融合阳性晚期实体瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=34b1189095d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2049795, encodeId=e8402049e95b1, content=<a href='/topic/show?id=321a1e8361c' target=_blank style='color:#2F92EE;'>#TRK融合#</a>, objectTitle=AACR 2020：拉罗替尼治疗TRK融合肿瘤的亚组分析, objectType=article, longId=193161, objectId=31991931618c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=31991931618c, replyNumber=0, likeNumber=49, createdTime=2020-11-10, rootId=0, userName=Tommy1949, userId=e5bc315, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=31991931618c, moduleTitle=AACR 2020：拉罗替尼治疗TRK融合肿瘤的亚组分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=31991931618c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2049796, encodeId=e2392049e96cb, content=<a href='/topic/show?id=321a1e8361c' target=_blank style='color:#2F92EE;'>#TRK融合#</a>, objectTitle=FDA批准FoundationOne CDx作为Vitrakvi（larotrectinib）的伴随诊断剂，以帮助鉴定NTRK融合阳性患者, objectType=article, longId=202449, objectId=39aa20244938, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=39aa20244938, replyNumber=0, likeNumber=44, createdTime=2021-01-30, rootId=0, userName=Tommy1949, userId=e5bc315, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=39aa20244938, moduleTitle=FDA批准FoundationOne CDx作为Vitrakvi（larotrectinib）的伴随诊断剂，以帮助鉴定NTRK融合阳性患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=39aa20244938)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2049792, encodeId=05e02049e925d, content=<a href='/topic/show?id=321a1e8361c' target=_blank style='color:#2F92EE;'>#TRK融合#</a>, objectTitle=NEJM：Larotrectinib对TRK融合阳性肿瘤治疗效果显著, objectType=article, longId=130286, objectId=a7911302861d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a7911302861d, replyNumber=0, likeNumber=40, createdTime=2018-08-06, rootId=0, userName=Tommy1949, userId=e5bc315, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a7911302861d, moduleTitle=NEJM：Larotrectinib对TRK融合阳性肿瘤治疗效果显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a7911302861d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2049793, encodeId=43162049e93e2, content=<a href='/topic/show?id=321a1e8361c' target=_blank style='color:#2F92EE;'>#TRK融合#</a>, objectTitle=Lancet oncol：Larotrectinib用于携带TRK融合基因的肿瘤患儿，疗效明显且耐受性好, objectType=article, longId=133863, objectId=6f041338630c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f041338630c, replyNumber=0, likeNumber=36, createdTime=2018-12-08, rootId=0, userName=Tommy1949, userId=e5bc315, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f041338630c, moduleTitle=Lancet oncol：Larotrectinib用于携带TRK融合基因的肿瘤患儿，疗效明显且耐受性好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6f041338630c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2049791, encodeId=f4522049e913d, content=<a href='/topic/show?id=321a1e8361c' target=_blank style='color:#2F92EE;'>#TRK融合#</a>, objectTitle=靶向NTRK融合基因新药LOXO-101有望用于治疗数种癌症, objectType=article, longId=67378, objectId=7a066e37829, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a066e37829, replyNumber=0, likeNumber=46, createdTime=2016-07-27, rootId=0, userName=Tommy1949, userId=e5bc315, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a066e37829, moduleTitle=靶向NTRK融合基因新药LOXO-101有望用于治疗数种癌症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7a066e37829)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

TRK融合

2020-05-29

Tommy1949 (审核中...)

前往app查看评论内容

#TRK融合#

JCO Precision Oncol：NTRK融合在儿童肿瘤中比预期的更常见

2021-05-03

Tommy1949 (审核中...)

前往app查看评论内容

#TRK融合#

Lancet Oncol：Larotrectinib治疗TRK融合阳性晚期实体瘤

2020-08-15

Tommy1949 (审核中...)

前往app查看评论内容

#TRK融合#

AACR 2020：拉罗替尼治疗TRK融合肿瘤的亚组分析

2020-11-10

Tommy1949 (审核中...)

前往app查看评论内容

#TRK融合#

FDA批准FoundationOne CDx作为Vitrakvi（larotrectinib）的伴随诊断剂，以帮助鉴定NTRK融合阳性患者

2021-01-30

Tommy1949 (审核中...)

前往app查看评论内容

#TRK融合#

NEJM：Larotrectinib对TRK融合阳性肿瘤治疗效果显著

2018-08-06

Tommy1949 (审核中...)

前往app查看评论内容

#TRK融合#

Lancet oncol：Larotrectinib用于携带TRK融合基因的肿瘤患儿，疗效明显且耐受性好

2018-12-08

Tommy1949 (审核中...)

前往app查看评论内容

#TRK融合#

靶向NTRK融合基因新药LOXO-101有望用于治疗数种癌症

2016-07-27

科室
- - 订阅+
  - 更多科室
工具
服务